title: Regulation of phospholipase D activity and phosphatidic acid production after purinergic (P2Y6) receptor stimulation.
abstract: Phosphatidic acid (PA) is a lipid second messenger located at the intersection of several lipid metabolism and cell signaling events including membrane trafficking, survival, and proliferation. Generation of signaling PA has long been primarily attributed to the activation of phospholipase D (PLD). PLD catalyzes the hydrolysis of phosphatidylcholine into PA. A variety of both receptor-tyrosine kinase and G-protein-coupled receptor stimulations have been shown to lead to PLD activation and PA generation. This study focuses on profiling the PA pool upon P2Y6 receptor signaling manipulation to determine the major PA producing enzymes. Here we show that PLD, although highly active, is not responsible for the majority of stable PA being produced upon UDP stimulation of the P2Y6 receptor and that PA levels are tightly regulated. By following PA flux in the cell we show that PLD is involved in an initial increase in PA upon receptor stimulation; however, when PLD is blocked, the cell compensates by increasing PA production from other sources. We further delineate the P2Y6 signaling pathway showing that phospholipase Cβ3 (PLCβ3), PLCδ1, DGKζ and PLD are all downstream of receptor activation. We also show that DGKζ is a novel negative regulator of PLD activity in this system that occurs through an inhibitory mechanism with PKCα. These results further define the downstream events resulting in PA production in the P2Y6 receptor signaling pathway.
authors.affiliation: Department of Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA.
authors.forename: Sarah A
authors.initials: SA
authors.lastname: Scott
authors.forename: Yun
authors.initials: Y
authors.lastname: Xiang
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Mathews
authors.forename: Hyekyung P
authors.initials: HP
authors.lastname: Cho
authors.forename: David S
authors.initials: DS
authors.lastname: Myers
authors.forename: Michelle D
authors.initials: MD
authors.lastname: Armstrong
authors.forename: Keri A
authors.initials: KA
authors.lastname: Tallman
authors.forename: Matthew C
authors.initials: MC
authors.lastname: O'Reilly
authors.forename: Craig W
authors.initials: CW
authors.lastname: Lindsley
authors.forename: H Alex
authors.initials: HA
authors.lastname: Brown
mesh_terms: D020001:1-Butanol / Q000494:pharmacology; D015153:Blotting, Western; D045744:Cell Line, Tumor; D019852:Diacylglycerol Kinase / Q000235:genetics / Q000378:metabolism; D004075:Diglycerides / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D006868:Hydrolysis; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D013058:Mass Spectrometry; D008954:Models, Biological; D010712:Phosphatidic Acids / Q000096:biosynthesis*; D010713:Phosphatidylcholines / Q000378:metabolism*; D054803:Phospholipase C delta / Q000235:genetics / Q000378:metabolism; D010739:Phospholipase D / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D051571:Protein Kinase C-alpha / Q000235:genetics / Q000378:metabolism; D034622:RNA Interference; D018048:Receptors, Purinergic P2 / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D014530:Uridine Diphosphate / Q000494:pharmacology
chemical_list: D004075:Diglycerides; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D010712:Phosphatidic Acids; D010713:Phosphatidylcholines; D018048:Receptors, Purinergic P2; C099845:purinoceptor P2Y6; D014530:Uridine Diphosphate; D020001:1-Butanol; C526463:DGKZ protein, human; D019852:Diacylglycerol Kinase; D051571:Protein Kinase C-alpha; C518024:PLCD1 protein, human; D054803:Phospholipase C delta; D010739:Phospholipase D
keywords: DAG Kinase; Diacylglycerol; Lipidomics; Phosphatidic Acid; Phospholipase D; Protein Kinase C (PKC); Purinergic Receptor